Svetlana Villevalde

Prof. Svetlana Villevalde

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in The Lancet
Verified
Journal Article
Closed access
HGHertzel C Gerstein
Hertzel C Gerstein
HCHelen M Colhoun
Helen M Colhoun
GDGilles R Dagenais
Gilles R Dagenais
RDRafael Diaz
Rafael Diaz
MLMark Lakshmanan
Mark Lakshmanan
WZWilliam Zigrang
William Zigrang

1 July 2019 in The Lancet
Verified
Journal Article
Closed access
HGHertzel C Gerstein
Hertzel C Gerstein
HCHelen M Colhoun
Helen M Colhoun
GDGilles R Dagenais
Gilles R Dagenais
RDRafael Diaz
Rafael Diaz
MLMark Lakshmanan
Mark Lakshmanan
WZWilliam Zigrang
William Zigrang

6 April 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ZKZh. D. Kobalava
Zh. D. Kobalava
AKA. O. Konradi
A. O. Konradi
SNS. V. Nedogoda
S. V. Nedogoda
ESE. V. Shlyakhto
E. V. Shlyakhto
GAG. P. Arutyunov
G. P. Arutyunov
ЮГЮ. И. Гринштейн
Ю. И. Гринштейн
Arterial hypertension in adults. Clinical guidelines 2020

6 April 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ESE. V. Shlyakho
E. V. Shlyakho
AKA. O. Konradi
A. O. Konradi
GAG. P. Arutyunov
G. P. Arutyunov
AAA. G. Arutyunov
A. G. Arutyunov
ABAndrei Evgen'evich Bautin
Andrei Evgen'evich Bautin
AYA. N. Yakovlev
A. N. Yakovlev
Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic

26 November 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
ESE. V. Shlyakhto
E. V. Shlyakhto
NZN. E. Zvartau
N. E. Zvartau
SVSvetlana Villevalde
Svetlana Villevalde
AYA. N. Yakovlev
A. N. Yakovlev
AAAsiiat S Alieva
Asiiat S Alieva
ASA. E. Soloviev
A. E. Soloviev

5 September 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ESE. V. Shlyakhto
E. V. Shlyakhto
YBYuri Belenkov
Yuri Belenkov
SBSergey Boytsov
Sergey Boytsov
SVSvetlana Villevalde
Svetlana Villevalde
AGAlbert Galyavich
Albert Galyavich
EZE. A. Zorina
E. A. Zorina
Aim. To describe demographic and clinical laboratory characteristics, concomitant diseases and drug therapy of outpatients with heart failure (HF) in the Russian Federation.Material and methods. An interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation ("PRIORITET-CHF") was performed. The study included outpatients with HF followed by a general practitioner or cardiologist.Results. Data from 6255 patients were analyzed (31,3% of the study sample; median age, 65 years; men, 65%). HF with reduced ejection fraction (HFrEF) was diagnosed in 42,4%, HF with preserved EF — in 31,9%. In addition, 57,4% of patients were characterized by NYHA class II HF. The most common causes of HF were hypertension, coronary artery disease, and atrial fibrillation or flutter. Of the concomitant diseases, doctors most often reported chronic kidney disease (CKD) (43,2%), obesity (37,8%) and diabetes (26,7%) in HF.Conclusion. In the Russian Federation, among outpatients with HF, there was domination of men, HFrEF phenotype, NYHA class II. The relatively young mean age and frequent associations of HF with cardiovascular risk factors and diseases underscore the importance of timely prevention initiatives. The identified high proportion of patients with CKD requires special attention and separate analysis. Despite the relatively high prescription rate of certain classes of diseasemodifying therapy for HF, the prescription of optimal quadruple therapy and electrophysiological treatments for HFrEF is insufficient.